Related Experiment Video
Updated: May 21, 2026

12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Rituximab for autoimmune blistering diseases: recent studies, new insights
1Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
Rituximab, an anti-CD20 monoclonal antibody, has been successfully used off-label for treatment of autoimmune blistering diseases. We discuss rituximab mechanisms of action, host factors that may affect response to rituximab, and the efficacy and safety of rituximab in autoimmune blistering diseases, incorporating recent data on the use of rituximab in other autoimmune disease patients.

